The original instrument was prepared by Cheryl Cooper. The following digest, which
does not constitute a part of the legislative instrument, was prepared by Thomas L.
Tyler.
DIGEST
SB 84 Engrossed 2021 Regular Session Talbot
Proposed law requires any health coverage plan renewed, delivered, or issued for delivery, in this
state to include coverage for genetic or molecular cancer testing including but not limited to tumor
mutation testing, next generation sequencing, hereditary germline mutation testing,
pharmacogenomic testing, whole exome, genome sequencing and biomarker testing. Provides that
coverage may be subject to annual deductibles, coinsurance, copayment provisions consistent with
that established under the health coverage plan and that this coverage may be subject to applicable
evidence-based medical necessity criteria under the health plan.
Proposed law defines health coverage plan as any hospital, health, or medical expense insurance
policy, hospital or medical service contract, employee welfare benefit plan, contract, or other
agreement with a health maintenance organization or a preferred provider organization, health and
accident insurance policy, or any other insurance contract of this type in the state, including group
insurance plans, self-insurance plans, and the office of group benefits programs. Excludes a plan
providing coverage for excepted benefits in present law, limited benefit health insurance plans, and
short-term policies that have a term of less than 12 months.
Proposed law defines a biomarker and biomarker testing.
Proposed law applies to health coverage plans renewed, delivered, or issued for delivery in their state
on or after January 1, 2022.
Effective January 1, 2022.
(Adds R.S. 22:1028.3)
Summary of Amendments Adopted by Senate
Committee Amendments Proposed by Senate Committee on Insurance to the original bill
1. Removes provisions that the health plan include coverage for the cost of genetic or
molecular testing.
2. Adds biomarker testing to provisions regarding genetic or molecular testing for
cancer.
3. Provides that coverage may be subject to applicable evidence-based medical
necessity criteria. 4. Defines "biomarker" and ""biomarker testing".